Doctor's Note — Clinical Trial Summary

Generated by FindMyCure.ai on November 25, 2026 | For discussion with your oncologist

TRIAL

Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)

NCT ID: NCT04424719 Phase: NA Sponsor: Institut Curie Status: Recruiting

SUMMARY

Biomarkers search for early diagnosis of liver metastases in patients with uveal melanoma who benefit from a follow-up tailored to their personalized risk of relapse.

KEY ELIGIBILITY CRITERIA

- 1. Patient aged of 18 years or more.
- 2. Patient with uveal melanoma with high metastatic relapse risk defined as :
- * T2b/c/d ou e T3,
- * or chromosom 3 or chromosom 8 abnormality by CGH array.
- 3. Completion of treatment of the primary tumor d 2 months.
- 4. Patient able to comply with the schedule of visits and blood samples of the study.
- 5. Signed informed consent form or legal representative.
- 1. Patient without french social insurance.
- 2. Any social, medical or psychological condition making the research process impossible.

ENROLLMENT CONTACT

Marie-Emmanuelle Legrier, PhD
Institut Curie
Paris, France
Phone: 0156245649
Email: drci.promotion@curie.fr

Total sites: 1 | 1 currently recruiting

This document is for informational purposes only and does not constitute medical advice. Always discuss clinical trial decisions with your oncologist. Data sourced from ClinicalTrials.gov (NCT04424719) and public sources. Generated by FindMyCure.ai.